Beijing Launches Online OTC Purchases via Medical Insurance Accounts; Jiangsu Adds Assisted Reproductive Services to Insurance Coverage
Hinova pharma
Clinical-Stage Innovative Drug Developer
Argo
RNAi Drug Developer
Medicare drug purchasing services are becoming more convenient.
Starting from July 1, insured individuals in Beijing can use their personal medical insurance accounts to purchase over-the-counter medications online from 300 designated retail pharmacies through the Meituan and JD.com platforms.
This change represents an important development opportunity for online pharmaceutical sales channels. How should pharmaceutical companies seize this opportunity?
An increasing number of provinces and cities in China have begun to pay attention to and support the assisted reproductive field.
For example, starting from July 1, Jiangsu Province will include 13 auxiliary reproductive medical projects and specialized painless delivery programs into the scope of medical insurance reimbursement. For the assisted reproductive industry chain, although it faces fierce competition, market opportunities are also increasing.
In terms of industrial investment, Maotai Group is also expanding its business scope.
On July 1, according to Tianyancha information, Maotai Jinshe (Guizhou) Biotechnology Industry Fund Partnership (Limited Partnership) was officially established, with its executive partner being Jinshe Investment Co., Ltd., and a registered capital as high as 1.5 billion RMB. Partner information shows that the fund was jointly funded by Maotai Jinshe (Guizhou) Industrial Development Fund Partnership (Limited Partnership) and others.
In the past day, what are the hot topics in the pharmaceutical market worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Another Province in China to Include Assisted Reproductive Technology in Medical Insurance
Starting from July 1, 13 assisted reproductive medical projects and specialized painless delivery projects in Jiangsu will be included in medical insurance.
2) Beijing Launches Online Medication Purchases Using Personal Medical Insurance Accounts at 300 Pharmacies
Starting from July 1, Beijing insured individuals can use their personal medical insurance accounts to purchase over-the-counter medications online from 300 designated retail pharmacies via the Meituan and JD.com platforms.
/ 02 /
Capital Information
1) Moutai Establishes Biotechnology Industry Fund
On July 1, Tianyancha showed that Maotai Jinshe (Guizhou) Biotechnology Industry Fund Partnership (Limited Partnership) was established, with Jinshe Investment Co., Ltd. as the executive partner, and a registered capital of 1.5 billion RMB. The partner information showed that the fund was jointly funded by Maotai Jinshe (Guizhou) Industrial Development Fund Partnership (Limited Partnership), etc.
2) Changfeng Pharmaceuticals' STAR Market IPO Terminated
On June 29, according to the official website of the Shanghai Stock Exchange, the application for the STAR Market listing of Changfeng Pharmaceuticals Co., Ltd. (referred to as: Changfeng Pharmaceuticals) was terminated.
/ 03 /
Pharmaceutical News
1) Hinova Pharma's HP518 Tablets Granted Fast Track Designation by U.S. FDA
On June 30, Hinova Pharmaceuticals Inc. announced that HP518, a PROTAC (Protein Degradation Targeting Chimera) drug, has been granted Fast Track designation by the U.S. FDA for the treatment of androgen receptor (AR)-positive triple-negative breast cancer.
2) The CXCR4 antagonist introduced by Yuheng Bio has been implemented in the Boao area of Hainan.
On July 1, Yuheng Bio announced that its core product, the innovative cell drive factor receptor CXCR4 antagonist Motepeptide, has recently been approved by the Hainan Provincial Drug Administration and obtained the import permit for urgently needed clinical drugs.
3) Argo's siRNA New Drug Completes First Subject Dosing in Phase 1 Clinical Trial
On July 1, Argo Biopharma announced that the first patient dosing in the Phase 1 clinical trial in China for the siRNA drug BW-03 targeting chronic hepatitis B was completed on June 27, 2024.
4) Huadong Medicine's HDM2005 Injection Clinical Trial Application Approved by U.S. FDA
On July 1, Huadong Medicine announced that the clinical trial application for the injectable drug HDM2005 submitted by its wholly-owned subsidiary, Zhongmei Huadong, has been approved by the U.S. FDA, allowing the Phase I clinical trial to be conducted in the United States.
/ 04 /
Instrument Tracking
1) The review of the registration termination for Cortea Bio's cross-linked sodium hyaluronate gel for injection
On July 1, according to the NMPA website, the registration review of Kaiteng Bio's Cross-linked Sodium Hyaluronate Gel for Injection was terminated.
2) Smith & Nephew's knee replacement surgery navigation system approved for marketing
On July 1, according to the NMPA website, Smith & Nephew's knee replacement surgery navigation system was approved for marketing.
3) ResMed ventilator approved for marketing
On July 1, according to the NMPA website, ResMed ventilator was approved for marketing.
4) Aibornode Preloaded Artificial Lens Approved for Marketing
On July 1, according to the NMPA website, Aibono Preloaded Artificial Lens was approved for marketing.
5) Daobo Medical's Titanium Plate Fixation System with Buttons Approved for Marketing
On July 1, according to the NMPA website, Dabo Medical's titanium plate fixation system with loops was approved for marketing.
6) Chunli Zhengda Medical Modular Hip Prosthesis Approved for Marketing
On July 1, according to the NMPA website, Chunli Zhengda Medical's modular hip prosthesis was approved for marketing.
/ 05 /
Overseas Pharmaceutical News
1) Alzheimer's Disease Oral Tau Protein Targeted Therapy Submitted for Market Approval
On July 1, TauRx Pharmaceuticals announced the submission of a UK marketing authorization application for Hydromethylthionine Mesylate, a Tau aggregation inhibitor, for the treatment of mild cognitive impairment and mild to moderate dementia caused by Alzheimer's disease.
2) BMS Terminates FRα ADC Collaboration with Eisai
On July 1, Eisai announced that due to BMS's product portfolio prioritization, the company has agreed to terminate the global strategic collaboration with BMS for the co-development and co-commercialization of the folate receptor α-targeted ADC drug farletuzumab ecteribulin.
Text / Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
